Drug Trial Radar · NCT04471064
A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 15, 2020
Primary completion
Feb 2024
Study completion Feb 2024
Sponsor
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Proswell Medical Corporation
- First posted
- Jul 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML; 2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the treatment of relapsed / refractory AML subjects. 3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects; 4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed / refractory AML patients; 5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML subjects.
Conditions
- Acute Myeloid Leukemia
Interventions
XY0206Drug
Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerable doseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Dose limiting toxicityTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Adverse eventTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Adverse drug reactionsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Serious adverse eventsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Urine routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Stool routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood biochemistryTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Serum amylase / lipaseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Coagulation functionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- ECGTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- EchocardiographyTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Imaging examinationTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Body temperatureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Blood pressureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Heart rateTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- BreathingTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- SkinTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- HeadTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- NeckTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- ChestTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- AbdomenTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- LimbsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- NervesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
- Back/spineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.